80 results
8-K
EX-99.1
VXRT
Vaxart Inc
13 May 24
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
4:03pm
the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines
8-K
EX-99.1
VXRT
Vaxart Inc
30 Apr 24
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
4:22pm
to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its
8-K
EX-99.1
VXRT
Vaxart Inc
14 Mar 24
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
4:05pm
and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform
8-K
EX-99.1
itn0hdle6eikye9e
6 Mar 24
Vaxart, Inc. Appoints Steven Lo as New President, Chief Executive Officer, and Director
9:23am
8-K
EX-99.1
94b1nv eqmresm
19 Jan 24
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
5:14pm
8-K
EX-99.1
ybrk9y 876ll7qa5rnou
16 Jan 24
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
5:18pm
8-K
EX-99.1
4vta9g 3t0ezjwk
16 Jan 24
Vaxart, Inc. Announces Management Change
9:19am
8-K
EX-99.1
3586d8nks
2 Nov 23
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
imu62a7k
6 Sep 23
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
4:43pm
8-K
EX-99.1
aum0 j3a4xvegwjtw915
3 Aug 23
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
4:20pm
8-K
EX-99.1
uz256eoiow54sls
10 Jul 23
Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate
4:12pm
DEFA14A
qznny9lk3u3t
21 Jun 23
Additional proxy soliciting materials
5:18pm
8-K
EX-99.1
00m9t2
8 Jun 23
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
4:27pm
8-K
EX-99.2
y31ecq934
8 Jun 23
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
4:27pm
8-K
EX-99.1
pnw s14f6we9t4i
6 Jun 23
No Vaccine Related Serious Adverse Events (SAEs) reported to date
8:07am
8-K
EX-99.1
66hbd
9 May 23
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results
4:57pm
8-K
EX-99.1
yqbfgor cp9zuxz1
19 Dec 22
Vaxart Names Phillip Lee as Chief Financial Officer
5:25pm
8-K
EX-99.1
k8dfuxkfm r0a1fyr
6 Dec 22
Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers
4:21pm